Kornimate/medical-research-clean huggingface dataset:
serial bnp testing for heart failure management

Conditions: Heart Failure

Summary: the scope of the use-bnp trial is to investigate whether knowledge of bnp measurements, in conjunction with clinical assessment, in the outpatient setting can guide the management of therapy in patients with heart failure.


Eligibility criteria:
inclusion criteria: * eligible subjects must be diagnosed with heart failure and have an abnormal bnp reading.

Keywords: heart failure bnp natriuretic peptide
proteomic analysis of human hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: this is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in asian patients with hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: arm a: hepatocellular carcinoma with vessel invasion: * hepatocellular carcionoma, pathologic diagnosed. * image documented vessel invasion, including portal vein thrombosis * eligible for surgical intervension. arm b: hepatocellular carcinoma without vessel invasion: * hepatocellular carcinoma, pathologic diagnosed or clinical diagnosed according to easl criteria. * no vessel invasion on image. arm c: healthy hepatitis carrier: * patients age \>18 years old with hepatitis b or c * normal liver function.

Keywords: carcinoma, hepatocellular portal vein proteomics
a study to evaluate the safety and tolerability of maximal use ruxolitinib cream

Conditions: Prurigo Nodularis

Summary: this study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with prurigo nodularis (pn).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of pn ≥ 3 months before screening. * pruriginous lesions (defined as papules, nodules, plaques, umbilicated lesions, and linear lesions) on ≥ 2 different body areas (such as right and left leg) at screening and baseline. * total estimated treatment bsa ≥ 25% (excluding the scalp) at screening and baseline. * iga-cpg-s score of ≥ 2 at screening and baseline. * baseline pn-related wi-nrs score ≥ 7. baseline wi-nrs score is defined as the 7-day average of wi-nrs scores before day 1 (data from a minimum of 4 out of 7 days prior to day 1 is needed). exclusion criteria: * chronic or acute pruritus due to a condition other than pn. * active ad lesions (signs and symptoms other than dry skin) within 6 months of screening and baseline. * acute or chronic active hbv or hcv infection. * any underlying condition known to be associated with the clinical presentation of pn that is not under control (stable) prior to the baseline visit. * any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: prurigo nodularis pn ruxolitinib
early predictors of necrotizing enterocolitis in neonates

Conditions: Necrotizing Enterocolitis

Summary: the goal of this project is to identify neonates who are predisposed to necrotizing enterocolitis (nec). the investigators will determine the effectiveness of non-invasive measures as well as biochemical markers to identify neonates early in the disease process. thus, the investigators aim to identify infants with nec prior to the onset of symptoms to institute or test treatments in the long term to prevent the progression of the disease in these infants.

the study will enroll premature, low birth weight infants in the neonatal intensive care units (nicu). potential study subjects will be identified upon delivery, or transfer to the nicu, and notification by the neonatology service. infants born at less than 30 weeks gestational age, birth weight less than or equal to 1500 grams will be eligible for enrollment in the study. the purpose of the study designed is to compare the splanchnic tissue oxygenation index and gut inflammatory biomarkers of patients with any stage of nec with healthy controls. since we will not be able to determine which patients will develop nec a priori, we will anticipate enrolling up to 450 neonates to identify 15 neonates with nec.

Eligibility criteria:
inclusion criteria: * infants born at ≤30 weeks gestational age and/or * infants with a birth weight ≤1500 grams exclusion criteria: * gestational age at birth greater than 30 weeks * obvious dysmorphic syndromes * any abdominal wall defect including omphalocele or gastroschisis * any known intestinal atresia * complex cardiac abnormalities * any known lethal chromosomal abnormalities

Keywords: nec, tissue oxygenation, gut inflammation
retrospective analysis of tem and tem-esd for the treatment of rectal adenomas and early rectal cancer

Conditions: Perioperative and Long-term Outcomes of TEM and TEM-ESD

Summary: we retrospectively analysed all tem and tem-esd procedures that took place in surgical clinic of the municipal hospital of karlsruhe and the surgery department of the university hospital of mannheim from 2007 to 2021. we evaluated the periopüerative and long-term outcomes of both procedures for adenomas, adenocarcinomas and other tumours seperately and we compared the results between the two techniques.


Eligibility criteria:
inclusion criteria: * patients who underwent tem or tem-esd exclusion criteria: -
different methods for reducing buccal infiltration local anesthesia injection pain

Conditions: Dental Caries in Children

Summary: local anesthetic injection is considered one of the most annoying dental procedures. the use of topical anesthesia is considered a routine procedure in the dental clinic especially for children. however, the taste and application procedure of the topical gel may not be pleasant for all children. the introduction of the buzzy device is considered a distraction measure in the medical field. alanazi et al., 2019, studied the effect of using the buzzy device with cold and vibration compared to the conventional infiltration technique using 30-gauge needle. they concluded that the use of the buzzy device resulted in better patients' acceptance and significantly lower wong-baker scores. ballard et al., 2019, mentioned in their systematic review the efficacy of the buzzy device for pain management during needle-related procedures, they concluded that the use of the device may be promising. ghaderi et al., 2013, evaluated the effect of cooling the injection site on pain perception before infiltration of local anesthetics. they found that cooling the injection site before infiltration of local anesthetics in the buccal mucosa for 1 min, reduced pain perceived by pediatric patients.

the investigators used the topical anesthesia, buzzy device (using vibration only and using cold and vibration) or precooling on pain during buccal infiltration local anesthesia injection.

Eligibility criteria:
inclusion criteria: * children in the mixed dentition stage, * age range 6-12 years old, * need extraction to a maxillary molar, * cooperative and medically free. exclusion criteria: * exclusion will be performed if the parent refused the participation of their children in the research.

Keywords: local anesthesia buzzy topical anesthesia pain precooling
video distraction to decrease use of sedation in pediatric participants during radiation therapy

Conditions: Malignant Neoplasm

Summary: this phase i pilot trial studies how well video distraction works to decrease the use of sedation in pediatric participants during radiation therapy. radiation treatment requires participants to lie very still (for accuracy). many children cannot do this without sedation. watching movies during radiation may distract children so they don't need sedation to complete treatment.

primary objective: i. to determine if the use of video distraction during radiation therapy (vidrt) during radiation for patients ages 3 to 13 decreases the rate of sedation use compared to patients previously treated without vidrt. secondary objective: i. to determine which variables are associated with decreased need for sedation use. variables will include patient age, length of treatment time (number of treatments and beam-on time), oncologic diagnosis, use of immobilization devices, pre-existing developmental or psychiatric diagnoses (attention deficit hyperactivity disorder \[adhd\], dissociative disorders \[dd\], anxiety, depression, developmental delay, learning disability), pain scale ratings at time of first radiation treatment (0-10). exploratory objectives: i. to determine the impact of vidrt on patient-reported quality of life prior to starting, during, and at the end of treatment using the pediatric quality of life inventory surveys including the pediatric quality of life inventory (pedsql) - 4.0 core and peds ql- 3.0 brain tumor questionnaires. ii. to determine the impact of vidrt on patient-reported anxiety throughout radiation treatment as monitored by patient-reported outcomes measurement information system (promis) pediatric item bank version (v) 2.0 anxiety questionnaire. iii. to determine if workup assessment category for patient being low, medium, or high risk of needing sedation correlates to actual sedation use. outline: participants undergo daily radiation therapy and watch videos/movies of their choice during treatments.

Eligibility criteria:
inclusion criteria: * all races and genders will be included. * patients with all tumor types will be included. exclusion criteria: * patients \ 13 years of age will be excluded. * patients with underlying movement disorders will be excluded.
a study of the trigeminal cardio-reflex in endodontic and other dental treatment

Conditions: Pulpitis

Summary: this study sought to comprehend the relationship between syncope and dental related therapy. if the relationship between dental related therapies and syncope is proved, clinical dentists will be remained to monitor changes of patient's blood pressure during root canal procedure.

this study sought to comprehend the relationship between syncope and dental related therapy. if the relationship between dental related therapies and syncope is proved, clinical dentists will be remained to monitor changes of patient's blood pressure during root canal procedure. previous trigemino-cardiac reflex(tcr) related studies reported that stimulation of trigeminal nerve induces trigeminal nerve reflection, and then causes blood pressure rapidly decreasing. finally, sudden blood pressure decreasing results in syncope. clinical data has been collected and analyzed in the past four months, and the primary results showed significantly difference. this phenomenon may be probably observed in other dental treatments. hence, the objective of this study is to remind clinical dentists to monitor patients' physical conditions when conducting root canal relevant treatments and to avoid situations such as syncope, and reduce medical disputes and benefit dentists and patient as a result. in the recent year, syncope often occurs during denture procedures. the value of this study will inform clinical dentist to notice risk of dental relative treatments. in addition, it will improve patients' safety.

Eligibility criteria:
inclusion criteria: * patients who sign the informed consent forms * patients with pulpitis * patients aged 20 or order exclusion criteria: * patients aged under 20

Keywords: pulpitis syncope trigeminal cardio-reflex
platelet reactivity after an eastern asian loading dose of prasugrel in taiwanese acs patients

Conditions: Acute Coronary Syndrome; Hemorrhage; Treatment Side Effects

Summary: prasugrel has a faster onset of action and greater platelet inhibition with less inter-individual response variability than clopidogrel. japan and taiwan are the only two nations where adjusted/asian dose of prasugrel (loading dose (ld)/maintenance (md): 20/3.75 mg) was approved for clinical use. however, there is no data regarding the effectiveness of adjusted dose of prasugrel on platelet reactivity in taiwanese patients with acute coronary syndrome (acs). this study aim to evaluate the pharmacodynamic of the asian dose prasugrel on the platelet reactivity after percutaneous coronary intervention (pci) for patients with acs.

rationale and background prasugrel provides more potent and rapid platelet inhibition compared to clopidogrel. rapid and effective inhibition of the platelet p2y12 receptor is of pivotal importance in patients with ami who undergo pci. prasugrel (60 mg loading and 10 mg/day maintenance dose) is a new generation p2y12 inhibitor that achieves greater and faster platelet inhibition comparing with clopidogrel in patients undergoing pci. as revealed by 2 head-to-head studies, reducing prasugrel dosages to 20/3.75 ld/md (mg) was still efficacious but led to less bleeding events than the original 60/10 ld/md (mg). in triton-timi 38 trial, prasugrel was associated with not only significantly less ischemic events but also more non-cabg timi major bleeding, as compared to clopidogrel. in the prasfit-acs study from japan (20 mg loading and 3.75 mg/day maintenance dose), prasugrel was associated with a 23% reduction of mace and the incidence of non-cabg major bleeding was similar to clopidogrel. there is no data regarding the effectiveness of japanese loading dose of prasugrel on platelet reactivity in taiwanese patients with ami. this study use pru for efficacy and isth major bleeding for safety evaluations; the anticipated results are prompt and effective platelet inhibition as well as comparably low bleeding rate.

Eligibility criteria:
inclusion criteria: * age\>=20 * mentally competent to provide an informed consent. * a person being diagnosed with acute coronary syndrome and arranged for a percutaneous coronary intervention. exclusion criteria: * a history of hemorrhagic stroke at any time in the past. * active internal bleeding or has a history of a bleeding disorder (i.e. hemophilia). * severe liver disease; for example, cirrhosis.

Keywords: acute coronary syndrome prasugrel verifynow-p2y12 assay
comparative effectiveness of entresto (sacubitril/valsartan) versus acei/arb in de novo heart failure patients

Conditions: de Novo Heart Failure

Summary: this was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (hfref) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or continuing angiotensin-converting enzyme inhibitors (acei)/angiotensin receptor blocker (arb) therapy for hf in the united states (us) using the secondary source of data, optum electronic health records (ehr).


Eligibility criteria:
inclusion criteria: sacubitril/valsartan cohort: * prescribed sacubitril/valsartan within the identification period. * with at least one international classification of diseases, 9th revision (icd)-9 or 10th revision (icd-10) code for diagnosis of hf within 30 days prior to the index date (including index date), that had non-missing sex and year of birth data. * active in the database for 759 days prior to index. * with left ventricular ejection fraction (lvef) ≤ 40% known prior to index day (including index date). * that were treated as part of the integrated delivery network (idn). acei/arb cohort: * prescribed acei or arb within the identification period. * with at least one icd-9 or icd-10 code for diagnosis of hf within 30 days prior to the index date (including index date), that have non-missing sex and year of birth data. * active in the database for 759 days prior to index. * with lvef ≤ 40% known prior to index day (including index date). * that were treated as part of the idn. exclusion criteria sacubitril/valsartan cohort: * that were \< 18 years old at index date. * that were prescribed sacubitril/valsartan within the baseline period or identification period (whichever was earlier) at any time prior to the index date (excluding). * with one or more icd-9 or icd-10 codes for diagnosis of hf within the baseline period, excluding the 30 days prior to index in which hf was initially identified (patient should have had no prior history of hf). * that were prescribed acei/arb \> 2 days before index date, and within 30 days after a hf diagnosis during the identification period (i.e. any patient included in the acei/arb cohort with an earlier index date, regardless of whether lvef was ≤ 40% or \> 40%) * with lvef ≤ 10% as the closest value to index date (including). acei/arb cohort: * that were \< 18 years old at index date. * that were prescribed sacubitril/valsartan within the baseline period or identification period (whichever was earlier) at any time prior to the index date, on the index date, or until ≤ 2 days after the index date. * with one or more icd-9 or icd-10 codes for diagnosis of hf within the baseline period, excluding the 30 days prior to index in which hf was initially identified (patient should have had no prior history of hf). * with lvef ≤ 10% as the closest value to index date (including).
combination study of urelumab and cetuximab in patients with advanced/metastatic colorectal cancer or advanced/metastatic head and neck cancer

Conditions: Colorectal Cancer; Head and Neck Cancer

Summary: the purpose of the study is to determine the safety, tolerability and maximum tolerated dose of urelumab in combination with cetuximab in patients with advanced/metastatic colorectal cancer or advanced/metastatic squamous cell carcinoma of the head and neck.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * subjects with advanced/metastatic colorectal cancer(crc) who have failed or been intolerant to both irinotecan- and oxaliplatin- based regimens * subjects with advanced/metastatic squamous cell carcinoma of the head and neck (scchn) who are without options for curative treatment * subjects must have measurable disease per response evaluation criteria in solid tumors (recist) 1.1 criteria * men and women 18 and older * women of childbearing potential (wocbp) and men must use highly effective methods of contraception * eastern cooperative oncology group (ecog) of 0 or 1 * subjects must have a life expectancy of at least 3 months exclusion criteria: * active or progressing brain metastases * other concomitant malignancies (with some exceptions per protocol) * nasopharyngeal carcinoma * active or history of autoimmune disease * positive test for human immunodeficiency virus (hiv) 1\&2 or known aids * history of any hepatitis (a,b or c) * known current drug or alcohol abuse * active tuberculosis (tb) * use of anti-cancer treatments within 28 days * prior therapy with anti-cd137 antibody other protocol defined inclusion/exclusion criteria could apply
left atrial geometry and outcomes after atrial fibrillation ablation

Conditions: Atrial Fibrillation; Recurrence

Summary: this is a multicenter observational 1-year retrospective cohort study evaluating the predictive value of the left atrial sphericity on the recurrence rate of atrial fibrillation after pulmonary vein ablation procedure. inclusion of consecutive patients undergoing af ablation during 2013 in whom a 3d-imaging of the left atrium (cardiac ct or mra) was acquired prior to the procedure and when procedural/follow-up data was prospectively collected.

validation of the predictive value of the left atrial sphericity for af recurrence of atrial fibrillation after a pulmonary vein ablation procedure in an external, multicenter cohort. in total, 9 centers will include consecutive patients who underwent af ablation from january to december 2013 in whom a 3d-imaging of the left atrium (cardiac ct or mra) was acquired prior to the procedure and when procedural/follow-up data was prospectively collected.

Eligibility criteria:
inclusion criteria: * \> 18 years old * first af ablation procedure * prior 3d-imaging of the left atrium (ct or mra) * prospective collection procedural and outcome data * obtention of informed consent exclusion criteria: * previous left atrial ablation or surgical procedure
evaluating the safety and efficacy of a outpatient appendectomy

Conditions: Appendicitis Acute; Appendectomy

Summary: this study evaluates the safety and efficacy of a outpatient appendectomy. half of participants will be perform the hospitalization, while the other half will undergo the outpatient appendectomy

acute appendicitis (aa) is one of the most common causes of acute abdomen and one of the most frequent diagnoses that require urgent surgery worldwide. many laparoscopic procedures are currently performed on an outpatient basis.laparoscopic appendectomy, however, continues to require postoperative hospitalization averaging between 1 and 2 days, at most institutions. at present ambulatory laparoscopic appendectomy (la) are gained popularity due to the improved understanding of patient selection criteria, the application of enhanced recovery pathways, and the potential for improving healthcare resource utilization. there are few studies about to compare the morbidity and readmission rates between ambulatory and conventional la. there is a lack of high-quality comparative studies making conclusive recommendations not possible at this time. based on current data, ambulatory la may be safe and feasible as compared with conventional la.

Eligibility criteria:
inclusion criteria: * patients over 14 years of age and who provide informed consent to participate in the study. * patients with non complicated acute appendicitis requiring and urgent appendectomy (laparoscopic or minimum incision) * negative appendicectomy. exclusion criteria: * complicated acute appendicitis (abscess, perforated, necrosis and peritonitis) * need to place intraoperative drainage. * patients with american society of anesthesiologists (asa) \>iv. * immunosuppressed patients. * pregnant. * possibility of inflammatory bowel disease. * no family support. * no informed consent signature. * impossibility to comply with the established follow-up